Colin Vale
YOU?
Author Swipe
View article: High incidence of impaired graft function after allogeneic HSCT for myelofibrosis, and successful utilization of stem cell boost
High incidence of impaired graft function after allogeneic HSCT for myelofibrosis, and successful utilization of stem cell boost Open
For myelofibrosis (MF) patient's undergoing hematopoietic stem cell transplant (HSCT) engraftment failure is a life-threatening challenge, largely due to primary graft failure (PGF) and/or prolonged poor graft function (PGFxn). Although me…
View article: Pentostatin Low-Dose TBI Is an Effective Conditioning Regimen That Permits Donor Engraftment in Patients with High Co-Morbidities Undergoing the First Transplant or Prior to a Second Transplant
Pentostatin Low-Dose TBI Is an Effective Conditioning Regimen That Permits Donor Engraftment in Patients with High Co-Morbidities Undergoing the First Transplant or Prior to a Second Transplant Open
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for malignant and nonmalignant hematological disease patients. Despite initial engraftment in the great majority of patients, the abilit…
View article: Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis
Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis Open
Introduction: Post-transplant cyclophosphamide given at 50 milligrams per kilogram on days 3 and 4 (full dose or FD-PTCy) is highly effective at preventing graft-versus-host disease (GVHD) but has been potentially associated with higher ra…